You searched for "choroideal"
Broadening of treatment options for potentially blinding retinal conditions
Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...Quality matters in the management of serious eye disorders
The author discusses the first quality standard for serious eye disorders from NICE and takes a look at new care models for enhanced service delivery. Patient backlogs pose risks to patient safety, with research showing that people are losing sight...A closer look at the new wave of glaucoma surgery – radical or old school?
Glaucoma is a challenging condition to treat because the exact pathophysiology remains unclear and the only readily modifiable factor is the intraocular pressure (IOP). Additionally, most glaucoma patients are completely asymptomatic, yet are often subjected to lifelong medical therapy. The...The eye without tears
The Art is long and Life is short. So goes the dispiriting tag in Latin and flung from day one and at regular intervals thereafter at idle medical students who, inevitably brainwashed, come by graduation to believe that the only...Strategies for managing neovascular AMD and DMO in routine clinical care
Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO) illustrate increasing adoption of patient-tailored treatment approaches based on initial diagnosis and regular monitoring of imaging and visual outcomes in routine clinical care. The...Genetic profiling for personalised healthcare solutions in AMD – an update
Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...Understanding and confronting bacterial endophthalmitis
Abdus Samad Ansari highlights the importance of early recognition of this condition using an unusual presentation. Endophthalmitis is a medical emergency with devastating consequences. Despite adequate treatment, severe cases frequently result in permanent blindness. Endophthalmitis involves inflammation of both the...Treatment of diabetic macular oedema
Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...Insights on medical AI for ophthalmology: an update on current perspectives
Artificial intelligence (AI) has immense promise for revolutionising medical practice. Generative AI is a form of AI in which algorithms are trained on datasets that can be used to generate new content, such as text, images or video based on...
Diclofenac versus Bromfenac after cataract surgery
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used after cataract surgery to reduce inflammation and cystoid macular oedema (CMO). Diclofenac 0.1% is used three to five times daily for 28 days and Bromfenac 0.09% twice daily for 14 days postoperatively. The...
